Pucotenlimab (Not yet branded)
Immunotherapy
Description
Pucotenlimab is an immunotherapy agent being developed for treatment of locally advanced rectal cancer in combination with radiation therapy and chemotherapy. Based on clinical trial data, it is designed to work in patients with both microsatellite instability-high (MSI-H) and microsatellite stable (MSS) colorectal tumors. The drug is being tested in neoadjuvant treatment protocols, where it is given before surgical resection to shrink tumors and improve surgical outcomes.
Mechanism of Action
Pucotenlimab appears to function as an immune checkpoint inhibitor, though its specific molecular target has not been fully disclosed in available clinical documentation. The drug is designed to enhance the immune system's ability to recognize and attack cancer cells by blocking inhibitory signals that tumors use to evade immune detection. This mechanism allows T-cells and other immune effector cells to mount a more effective anti-tumor response.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.